Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression time (months) No. of deaths Median survival time (months) Total Age73 (50-91) ≤ ≥ n.s.33nonen.s. TT142570all alive T T T n.s. NN N n.s.4399n.s. MM M n.s.9383n.s. Gleason score n.s. PSA at diagnosis174 ( ) < ≥ nonen.s. Nadir PSA level0.3 ( ) < ≥4≥ Time from PADT to nadir9.45 (1-64) ≥ < Time from PADT to CRPC 13 (1-97) No CRPC 79 14none ≥ < * P<0.05, ** P<0.005, *** all P<0.001, **** P<0.001 without CRPC v.s. ≥12 PADT: primary androgen deprivation therapy CRPC: castration resistant prostate cancer ** *** **** **

TABLE 2. Hazards Ratio Estimates and Confidence Intervals from Proportional Hazards Modeling of Progression to CRPC Univariate analysisMultivariate analysis Hazard Ratio95% C.I.P value Hazard Ratio95% C.I.P value Age TT11 T T T Gleason score PSA at diagnosis< ≥ Nadir PSA level< < <0.001 ≥4≥ < <0.001 Time from PADT to nadir≥ < <0.001 < < < % C.I.: 95% confidence interval PADT: primary androgen deprivation therapy CRPC: castration resistant prostate cancer

TABLE 3. Hazards Ratio Estimates and Confidence Intervals from Proportional Hazards Modeling of Overall Survival Univariate analysis Multivariate analysis Hazard Ratio95% C.I.P value Hazard Ratio95% C.I.P value Age Nadir PSA level< < ≥4≥ < <0.001 Time from PADT to nadir≥ < < <0.001 Time from PADT to CRPCNo CRPC11 ≥ < < < % C.I.: 95% confidence interval PADT: primary androgen deprivation therapy CRPC: castration resistant prostate cancer